Relmada Therapeutics Inc (RLMD) Total Business Assets

Graphic logo of Relmada (RLMD)

The price trend for the total assets of Relmada Therapeutics (RLMD) reflected in this chart is 120.09. Business efficiency relies on strict temperature control during the delivery of neuropreparations to preserve their properties. The development strategy is based on testing NMDA receptor blockers in various modes, which minimizes regulatory threats. Meanwhile, anticipation of the final trial results for the antidepressant will become a key growth driver, despite past failures.

Relmada Therapeutics (RLMD): Cumulative Company Assets from 07/04/2022 to 10/28/2026

Analytical breakdowns for Relmada (RLMD)

- price and consensus price forecast:
Share Price relmada.com|RLMD - Price Target Chart
- market capitalization data:
Market Capitalization Relmada Corp|RLMD - Enterprise Value
- book capitalization data:
Net Asset Value per Share Relmada Therapeutics|RLMD - Company Net Assets|Market Capitalization to Book Value Ratio relmada.com|RLMD - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Relmada Therapeutics|RLMD - Long-Term Debt to Equity|Current Liabilities to Capital Relmada Corp|RLMD - Company Debts|Debt to Net Assets Ratio Relmada Corp|RLMD - Company Long-Term Debts|Short-Term Debt Relmada Therapeutics
Analysis of all company metrics:Relmada Therapeutics
Finished products of Relmada Therapeutics, Inc.

This indicator represents a market valuation of the company's resources, calculated inversely via daily ROA based on current quotes, which allows for the analysis of future asset potential. By analyzing the trajectory of total balance sheet assets, an investor can assess the capitalization of the intellectual capital of Relmada Therapeutics (RLMD), which is supported by a stable staff of leading neurobiologists creating value through the development of innovative antidepressants.

Competing companies

BIIB (biogen.com) - Total Business Assets|Aggregate Company Assets Neurocrine Biosciences, Inc. (NBIX)|Total Business Assets Regencell Bioscience Ltd|Axsome Therapeutics Inc - Company Total Assets|Company Assets ACADIA Corp ACAD|Cumulative Company Assets XENE (Xenon Pharmaceuticals)|vikingtherapeutics.com - Company Total Assets|Aggregate Company Assets Supernus (SUPN)|CPRX: Aggregate Asset Value|Aggregate Company Assets DNLI|HRMY (Harmony Corp) - Company Assets|BHVN - Aggregate Company Assets|Aggregate Asset Value amylyx.com|Trevi Therapeutics, Inc. - Company Total Assets|Company Assets PRAX (Praxis Precision Medicines Inc)|Aggregate Company Assets Anavex Corp AVXL|CeriBell EEG - Aggregate Company Assets|PRTA: Aggregate Company Assets|ALEC - Cumulative Company Assets|ANNX: Company Total Assets|Omeros (OMER) - Company Total Assets|Company Total Assets Neurogene Corp (NGNE)|Total Business Assets AC Immune Inc|Company Total Assets VYGR|Company Total Assets neumoratx.com NMRA|Cumulative Company Assets Scilex|TVGN - Aggregate Asset Value|Cumulative Company Assets Alpha Cognition Corp ACOG|CGTX - Aggregate Business Assets|Company Total Assets Inhibikase Therapeutics IKT|cassavasciences.com (SAVA) - Aggregate Asset Value|Company Total Assets ASRT (Assertio Holdings)|Company Assets COYA|Vistagen Therapeutics (VTGN) - Aggregate Company Assets|Aggregate Asset Value ovidrx.com (OVID)|Company Total Assets ABOS (Acumen Pharmaceuticals)|cervomed.com - Company Total Assets|Aggregate Company Assets Alterity Therapeutics Ltd|CLNN - Total Asset Value of Company|Company Total Assets PEPG|Company Assets Jupiter Neurosciences, Inc.|ANVS (Annovis Bio, Inc.) - Cumulative Company Assets|Company Total Assets Grace Tx (GRCE)|Cumulative Company Assets Firefly Neuroscience|Aggregate Business Assets anewmeds.com (KLTO)|Company Total Assets NRSN|Company Total Asset Base Reviva Pharmaceuticals, Inc. RVPH|MTVA: Company Total Assets|NRXS: Cumulative Company Assets|heliusmedical.com - Aggregate Company Assets|PASG (Passage Bio) - Company Total Asset Base|NEUP - Aggregate Company Assets|Aggregate Asset Value NERV|Aggregate Company Assets Athira Pharma, Inc. (ATHA)|Aggregate Company Assets ADXN (addextherapeutics.com)|Alzamend Neuro - Aggregate Company Assets|Cumulative Company Assets Cyclerion Therapeutics Inc. CYCN|Protagenic (PTIX) - Company Total Assets|KTTA: Total Business Assets|Aggregate Company Assets cortigent.com|avenuetx.com (ATXI) - Total Business Assets|Company Total Assets BCLI (BrainStorm Cell Therapeutics)|Company Assets Cara Therapeutics Inc. (CARA)|Cumulative Company Assets CHRO|Company Total Assets ELYM (eliemtx.com)|Aggregate Company Assets Intra-Cellular Therapies, Inc.|longboardpharma.com - Aggregate Asset Value|MRNS (Marinus Pharmaceuticals, Inc.) - Aggregate Company Assets|NKGN: Company Assets|Aggregate Company Assets NeuroBo NRBO|Sage Therapeutics Inc (SAGE) - Aggregate Asset Value|Company Total Assets SNPX (Synaptogenix, Inc.)|Company Assets TRVN|Aggregate Company Assets Vigil Neuroscience (VIGL)|Aggregate Company Assets WENA (anewmeds.com)|Cerevel - Aggregate Company Assets